IP Library Granted Patent US 12,702,862
Granted Patent B2
US 12,702,862 · App. 18/914,202 · Granted Aug 11, 2026

Filtering eyewear and optics for ocular photo-bio-stimulation

Inventors: Ronald Blum (Atlanta, GA); Jack Loeb (Fisher Island, FL); Anita Broach (Christiansburg, VA)
Assignee: NEURORAYS, LLC
A61N5/0622G16H40/63A61N2005/0627A61N2005/063A61N2005/0648A61N2005/0653A61N2005/0654A61N2005/0656A61N2005/0663A61N2005/0667
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,702,862
App. No.
18/914,202
Filed
Oct 13, 2024
Granted
Aug 11, 2026
Kind
B2
Art Unit
3792
USPC
607/45
Abstract

A device providing ocular photo-bio-stimulation therapy.

Claims (28)

1 . A wearable eyewear device comprising a filtered lens or filtered optic, wherein the filtered lens or filtered optic provides a light transmission of 40% or more of ocular photo-bio-stimulation light through and measured within a light wavelength range of at least one of 480 nm+/−30 nm or 500 nm+/−20 nm, to an eye of a wearer of the wearable eyewear device, wherein the filtered lens or filtered optic further provides a visible light transmission (VLT) of 30% or less, and wherein the filtered lens or filtered optic provides for a visible light transmission percentage for a light wavelength range of 451 nm-495 nm that is 1.5 times or greater than a visible light transmission percentage for a light wavelength range of 496 nm-570 nm, and wherein a visible light transmission percentage for the light wavelength range of 496 nm-570 nm is 2.5 times or greater than a visible light transmission percentage for a light wavelength range of 571 nm-780 nm.

2 . The wearable eyewear device of claim 1 , wherein the ocular photo-bio-stimulation light transmitted by the filtered lens or filtered optic increases a production of dopamine, serotonin, or both, in an eye and/or a brain of the wearer of the wearable eyewear device as compared to conventional sunglasses.

3 . The wearable eyewear device of claim 1 , wherein the wearable eyewear device can be utilized on its own for daily wear and is a first eyewear, or wherein the first eyewear fits over, behind, or around, a second eyewear frame or a lens of the second eyewear frame, or wherein the wearable eyewear device is supported by or releasably attachable to the second eyewear frame or the lens of the second eyewear frame.

4 . The wearable eyewear device of claim 3 , wherein the eyeglass lens of the wearable device or the second eyewear frame comprises a central zone for correcting distance vision of the wearer of the wearable eyewear device, and wherein the eyeglass lens of the wearable device or the second eyewear frame comprises or is a lens comprising one or more of: H.A.L.T. technology (Highly Aspheric Lenslet Target), D.I.M.S. technology (Defocus Incorporated Multiple Segments), alternating optical rings for focus and defocus, light dispersion or diffusion, increased minus optical power of a peripheral zone of the eyeglass lens of the second eyewear frame compared to an optical power of the central zone, or a myopia control lens.

5 . The wearable eyewear device of claim 3 , wherein the eyeglass lens of the wearable device or the second eyewear frame comprises one or more of: rings of optical defocus, Fresnel rings, chromatic aberration focused lens technology, aspheric lenslets, micro-lenslets, a lenslet micro-array, nanoparticles or micro structured materials, or optical islands causing defocus or lack of focus.

6 . The wearable eyewear device of claim 3 , wherein the eyeglass lens of the second eyewear frame comprises optical power, and wherein the filtered lens or filtered optic of the wearable eyewear device comprises a plano optical power in a central zone.

7 . The wearable eyewear device of claim 3 , wherein the lens of the second eyewear frame corrects a wearer's vision, wherein the first eyewear fits around or over the second eyewear frame or the lens of the second eyewear frame, or wherein the first eyewear is supported by or attached to the second eyewear frame or the lens of the second eyewear frame.

8 . The wearable eyewear device of claim 1 , wherein the filtered lens or filtered optic comprises one or more of: an interference filter, an absorption filter, a light absorber, dye, a neutral density filter, a bandpass filter, a notch filter, or blue light filter.

9 . The wearable eyewear device of claim 1 , wherein the filtered lens or filtered optic primarily filters light within the light wavelength range of 480 nm+/−30 nm, and also filters light within light wavelength ranges of 580 nm+/−20 nm or 600 nm+/−30 nm, and wherein the filtered lens or filtered optic comprises a reddish-brown color tone or a greenish color tone.

10 . The wearable eyewear device of claim 1 , wherein the wearable eyewear device is one of: fit-over eyewear, disposable eyewear, clip-on eyewear, magnetically attachable eyewear, pressure-mounted eyewear, rollable eyewear, statically attachable eyewear, or eyewear.

11 . The wearable eyewear device of claim 1 , wherein the wearable eyewear device is sunglasses.

12 . The wearable eyewear device of claim 1 , wherein the filtered lens or filtered optic has an optical power or is plano (devoid of optical power).

13 . The wearable eyewear device of claim 1 , wherein the light intensity of the transmitted wavelengths within the range of 480 nm+/−30 nm or 500 nm+/−20 nm that passes through a last surface of the filtered lens or filtered optic closest to an eye of the wearer is 300 lux or greater.

14 . The wearable eyewear device of claim 1 , wherein ocular photo-bio-stimulation light transmitted through the filtered lens or filtered optic increases choroidal thickness and/or reduces or slows axial elongation of an eye of the wearer of the wearable eyewear device.

15 . The wearable eyewear device of claim 1 , wherein the ocular photo-bio-stimulation light transmitted through the filtered lens or filtered optic slows down myopia progression of an eye of the wearer of the wearable eyewear device.

16 . The wearable eyewear device of claim 1 , wherein the ocular photo-bio-stimulation light transmitted through the filtered lens or filtered optic excites rhodopsin and/or melanopsin of an eye of the wearer of the wearable eyewear device.

17 . The wearable eyewear device of claim 1 , further comprising one or more of: a timer, an alarm, a sound alarm, a vibration alarm, a light alarm, a light switch, wired or wireless communication to a remote third party, a computer processing unit, a sensor(s) for monitoring a physiological response of the wearer, or one or more sensors providing biofeedback of or from the wearer.

18 . The wearable eyewear device of claim 1 , further comprising a biofeedback component, wherein the biofeedback is a measurement of a size of a pupil or a blink rate of the wearer.

19 . The wearable eyewear device of claim 1 , wherein the filtered lens or filtered optic comprises an imbibed tint or a dye.

20 . The wearable eyewear device of claim 1 , wherein the filtered lens or filtered optic comprises a deposition coating or spin coating.

21 . The wearable eyewear device of claim 1 , wherein the filtered lens or filtered optic is a single vision lens or single vision optic or a multifocal lens or multifocal optic.

22 . The wearable eyewear device of claim 1 , wherein the filtered lens or filtered optic comprises a surface cast layer that filters light.

23 . The wearable eyewear device of claim 1 , wherein the filtered lens or filtered optic comprises a progressive addition lens topography.

24 . The wearable eyewear device of claim 1 , wherein the wearable eyewear device is one of spectacle eyewear, extended reality (XR) eyewear, modified reality eyewear, a Fresnel lens or optic, a contact lens, an intraocular lens, or a corneal implant.

25 . The wearable eyewear device of claim 1 , wherein the filtered lens or filtered optic comprises a blue light transmission percentage for the light wavelength range of 451 nm-495 nm that is 1.5 times or greater than the visible light transmission (VLT) through the filtered lens or filtered optic, and wherein the blue light transmission percentage is 1.5 times or greater than a green light transmission percentage within the range of 496 nm-570 nm.

26 . The wearable eyewear device of claim 1 , wherein the filtered lens or filtered optic complies with traffic signal light standards so that a wearer of the wearable eyewear device can sufficiently identify colors of stop lights, traffic lights, and/or other road signs or signals.

27 . The wearable eyewear device of claim 1 , further comprising one or more of: H.A.L.T. technology (Highly Aspheric Lenslet Target); D.I.M.S. technology (Defocus Incorporated Multiple Segments); alternating optical rings for focus and defocus; Fresnel optics or Fresnel rings; light dispersion or diffusion; the filtered lens or optic, wherein the filtered lens or optic has a central zone and at least one peripheral zone, wherein the at least one peripheral zone has one or more of increased minus optical power or increased plus optical power when compared to an optical power of the central zone; or a myopia control lens.

28 . The wearable eyewear device of claim 1 , wherein the photo-bio-stimulation light is emitted from at least one of: a light emitter, light emitters, light-emitting diodes (“LEDs”), organic LEDs (OLEDs), transparent organic LEDs, micro-organic LEDs (micro-oLEDs), micro-LEDs, ionic liquids for electrochemical devices (“iLEDs”), micro-iLEDSs, organic LEDs, quantum dots, fluorescent light, incandescent light, particles that fluoresce, ambient light, sunlight, or an electronic display.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2024
From: BLUM, RONALD; BROACH, ANITA; LOEB, JACK
To: NEURORAYS, LLC
Reel/Frame 068895/0701 →
Continuity (28)
Continuation 18827786 · Sep 8, 2024
Continuation 18827782 · Sep 8, 2024
Provisional Application 63697560 · Sep 22, 2024
Provisional Application 63684509 · Aug 19, 2024
Provisional Application 63676855 · Jul 29, 2024
Provisional Application 63674219 · Jul 22, 2024
Provisional Application 63673746 · Jul 21, 2024
Provisional Application 63671237 · Jul 14, 2024
Provisional Application 63654566 · May 31, 2024
Provisional Application 63648098 · May 15, 2024
Provisional Application 63639892 · Apr 29, 2024
Provisional Application 63569005 · Mar 22, 2024
Provisional Application 63561266 · Mar 4, 2024
Provisional Application 63553693 · Feb 15, 2024
Provisional Application 63553226 · Feb 14, 2024
Provisional Application 63550852 · Feb 7, 2024
Provisional Application 63627703 · Jan 31, 2024
Provisional Application 63623253 · Jan 20, 2024
Provisional Application 63617363 · Jan 3, 2024
Provisional Application 63609306 · Dec 12, 2023
Provisional Application 63603258 · Nov 28, 2023
Provisional Application 63600139 · Nov 17, 2023
Provisional Application 63548204 · Nov 12, 2023
Provisional Application 63546848 · Nov 1, 2023
Provisional Application 63541243 · Sep 28, 2023
Provisional Application 63540090 · Sep 24, 2023
Provisional Application 63537021 · Sep 7, 2023
Related Publication 20250082959A1 · Mar 13, 2025
References Cited (120)
US 3826751A · Laliberte · 1974 [cited by applicant]
US 5083858A · Girerd · 1992 [cited by applicant]
US 5243460A · Kornberg · 1993 [cited by applicant]
US 5838419A · Holland · 1998 [cited by examiner]
US 5923398A · Goldman · 1999 [cited by applicant]
US 6350275B1 · Vreman et al. · 2002 [cited by applicant]
US 8469512B2 · Croft et al. · 2013 [cited by applicant]
US 8833937B2 · Shehadeh et al. · 2014 [cited by applicant]
US 8911082B2 · Ambler · 2014 [cited by applicant]
US 9028064B2 · Harris · 2015 [cited by applicant]
US 9138595B2 · Savage et al. · 2015 [cited by applicant]
US 9720228B2 · Harrison et al. · 2017 [cited by applicant]
US 9885884B2 · Drobe · 2018 [cited by applicant]
US 10073283B2 · Legerton · 2018 [cited by applicant]
US 10152906B2 · Gutierrez · 2018 [cited by applicant]
US 10219944B2 · Tedford et al. · 2019 [cited by applicant]
US 10386654B2 · Marshall et al. · 2019 [cited by applicant]
US 10444505B2 · Rousseau et al. · 2019 [cited by applicant]
US 10884246B2 · Blum et al. · 2021 [cited by applicant]
US 10884264B2 · Hones et al. · 2021 [cited by applicant]
US 10895735B1 · Feinbloom et al. · 2021 [cited by applicant]
US 10942373B2 · Barrau et al. · 2021 [cited by applicant]
US 11029540B2 · To et al. · 2021 [cited by applicant]
US 11048103B2 · Saylor et al. · 2021 [cited by applicant]
US 11061255B2 · Lau et al. · 2021 [cited by applicant]
US 11065468B2 · Barrau et al. · 2021 [cited by applicant]
US 11086145B2 · Flinders · 2021 [cited by applicant]
US 11099408B2 · McCabe et al. · 2021 [cited by applicant]
US 11131869B2 · Marshall et al. · 2021 [cited by applicant]
US 11420072B2 · He et al. · 2022 [cited by applicant]
US 11446514B2 · Bahmani et al. · 2022 [cited by applicant]
US 11701315B2 · Ishak et al. · 2023 [cited by applicant]
US 11711600B2 · Han et al. · 2023 [cited by applicant]
US 11774784B2 · Barrau et al. · 2023 [cited by applicant]
US 12055797B2 · Newman et al. · 2024 [cited by applicant]
US 12336937B2 · Tedford et al. · 2025 [cited by applicant]
US 20020198577A1 · Jaillet · 2002 [cited by applicant]
US 20100033830A1 · Yung · 2010 [cited by applicant]
US 20100103371A1 · Sarver et al. · 2010 [cited by applicant]
US 20100152849A1 · Degenaar et al. · 2010 [cited by applicant]
US 20120200823A1 · Bandhauer et al. · 2012 [cited by applicant]
US 20130211178A1 · Brigatti et al. · 2013 [cited by applicant]
US 20140176898A1 · Yi et al. · 2014 [cited by applicant]
US 20140247423A1 · Drobe · 2014 [cited by applicant]
US 20150088231A1 · Rubinfeld et al. · 2015 [cited by applicant]
US 20150142086A1 · Narita · 2015 [cited by applicant]
US 20150234207A1 · Koifman · 2015 [cited by applicant]
US 20160022225A1 · Palmer et al. · 2016 [cited by applicant]
US 20160026005A1 · Flinders · 2016 [cited by examiner]
US 20160067086A1 · Tedford et al. · 2016 [cited by applicant]
US 20160216537A1 · Drobe · 2016 [cited by applicant]
US 20160270656A1 · Samec et al. · 2016 [cited by applicant]
US 20160361437A1 · Lucas et al. · 2016 [cited by applicant]
US 20170299898A1 · Gallina et al. · 2017 [cited by applicant]
US 20180035101A1 · Osterhout · 2018 [cited by examiner]
US 20190204624A1 · Barrau et al. · 2019 [cited by applicant]
US 20190212581A1 · Scherlen et al. · 2019 [cited by applicant]
US 20190258086A1 · Barrau et al. · 2019 [cited by applicant]
US 20210031051A1 · Kubota · 2021 [cited by examiner]
US 20210132416A1 · Newman · 2021 [cited by examiner]
US 20210157172A1 · Barrau et al. · 2021 [cited by applicant]
US 20210382325A1 · Kubota et al. · 2021 [cited by applicant]
US 20220047887A1 · Honold et al. · 2022 [cited by applicant]
US 20220057651A1 · Segre et al. · 2022 [cited by applicant]
US 20220062634A1 · Masko et al. · 2022 [cited by applicant]
US 20220075211A1 · Schmeder · 2022 [cited by examiner]
US 20220082860A1 · Guillot et al. · 2022 [cited by applicant]
US 20220111228A1 · Schoutens · 2022 [cited by applicant]
US 20220187628A1 · Valentine et al. · 2022 [cited by applicant]
US 20220233878A1 · Lee et al. · 2022 [cited by applicant]
US 20220252904A1 · Hones, Jr. et al. · 2022 [cited by applicant]
US 20220397774A1 · Barrau et al. · 2022 [cited by applicant]
US 20220413318A1 · Kubota et al. · 2022 [cited by applicant]
US 20230132952A1 · Youngblood et al. · 2023 [cited by applicant]
US 20230204982A1 · Boyles · 2023 [cited by examiner]
US 20230248937A1 · Blair et al. · 2023 [cited by applicant]
US 20230248993A1 · Bahmani et al. · 2023 [cited by applicant]
US 20230338742A1 · Pang · 2023 [cited by examiner]
US 20230389161A1 · Coleman · 2023 [cited by applicant]
US 20240036357A1 · Schianchi et al. · 2024 [cited by applicant]
US 20240272454A1 · Zheleznyak et al. · 2024 [cited by applicant]
US 20240359031A1 · Marshall et al. · 2024 [cited by applicant]
CN 103926710A · 2014 [cited by applicant]
CN 111938911A · 2020 [cited by applicant]
CN 212973238U · 2021 [cited by applicant]
EP 2772794A1 · 2014 [cited by applicant]
EP 3528036A1 · 2019 [cited by applicant]
EP 3528037A1 · 2019 [cited by applicant]
EP 4248925A2 · 2023 [cited by applicant]
EP 4296762A1 · 2023 [cited by applicant]
KR 20130006766U · 2013 [cited by applicant]
KR 102195466B1 · 2020 [cited by applicant]
KR 102436963B1 · 2022 [cited by applicant]
WO 2019109125A1 · 2019 [cited by applicant]
WO 2021105979A1 · 2021 [cited by applicant]
WO 2021116449A1 · 2021 [cited by applicant]
WO 2021252319A1 · 2021 [cited by applicant]
WO 2022094678A1 · 2022 [cited by applicant]
WO 2022187279A1 · 2022 [cited by applicant]
WO 2022219441A1 · 2022 [cited by applicant]
WO 2022258572A1 · 2022 [cited by applicant]
WO 2023186146A1 · 2023 [cited by applicant]
WO 2024094884A1 · 2024 [cited by applicant]
Cardinal Intellectual Property Patent Search Report dated Nov. 4, 2024. [cited by applicant]
Chakraborty, R., et al.; Axial length reduction and choroidal thickening with short-term exposure to cyan light in human subjects; Ophthalmic Physiol Opt. 2024;00:1-19. https://doi.org/10.1111/opo.13390. [cited by applicant]
National Academies of Sciences, Engineering, and Medicine. 2024. Myopia: Causes, Prevention, and Treatment of an Increasingly Common Disease. Washington, DC: The National Academies Press. https://doi.org/10.17226/27734. [cited by applicant]
Visible Bandpass Filters; Optical Filter Shop; retrieved at https://opticalfiltershop.com/product-category/bandpass-filter/visible-bandpass-filters-390nm-to-750nm/?srsltid=AfmBOoq17fx_K3qa6-4IEMggf0z4wh0-EXqLU41U1dkCunE… [cited by applicant]
Application No. PCT/US2024/051175, International Search Report and Written Opinion dated Nov. 25, 2024. [cited by applicant]
Application No. PCT/US2024/053151, International Search Report and Written Opinion dated Jan. 2, 2025. [cited by applicant]
Application No. PCT/US2024/056407, International Search Report and Written Opinion dated Jan. 17, 2025. [cited by applicant]
Application No. PCT/US2024/045750, International Search Report and Written Opinion dated Dec. 16, 2024. [cited by applicant]
Application No. PCT/US2024/045751, International Search Report and Written Opinion dated Dec. 16, 2024. [cited by applicant]
Application No. PCT/US2024/057354, International Search Report and Written Opinion dated Feb. 3, 2025. [cited by applicant]
Application No. PCT/US2025/012142, International Search Report and Written Opinion dated Mar. 5, 2025. [cited by applicant]
Capovilla, G.; Effectiveness of a particular blue lens on photoparoxysmal response in photosensitive epileptic patients; Ital J. Neurol Sci (1999) 20:161-166. [cited by applicant]
www.dopavision.com/product/, visited Sep. 11, 2024. [cited by applicant]
Akerman, D., Predicting the Onset of Myopia in Children, Review of Myopia Management, Jul. 15, 2024, https://reviewofmm.com/predicting-the-onset-of-myopia-in-children/, downloaded May 30, 2025. [cited by applicant]
Liu, Z., et al., The Effects of Repeated Low-Level Red-Light Therapy on the Structure and Vasculature of the Choroid and Retina in Children with Premyopia, Ophthalmol Ther 13:739-759 (2024), https://doi.org/10.1007/s401… [cited by applicant]
Lumivision & Wellbeing: Myproclear webpage; https://lumi-visionandwellbeing.co.uk/red-light-therapy-for-myopical-control/; downloaded May 19, 2025. [cited by applicant]
Mutti, D., et al., Predicting the onset of myopia in children by age, sex, ethnicity: Results from the Cleere Study, Optom Vis Sci. Apr. 1, 2024;101(4):179-186, https://pmc.ncbi.nlm.nih.gov/articles/PMC11060695/, downlo… [cited by applicant]